Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bakris

Showing results (641-650 of 738) with videos related to

Pageof 74
Sort By:
Kidney Medicine|December 4, 2023
Finerenone in Black Patients With Type 2 Diabetes and CKD: A Post hoc Analysis of the Pooled FIDELIO-DKD and FIGARO-DKD TrialsJohn M Flack, Rajiv Agarwal, Stefan D Anker, et al.
The American Journal of Medicine|July 3, 2007
Body weight changes with beta-blocker use: results from GEMINIFranz H Messerli, David S H Bell, Vivian Fonseca, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 17, 2023
Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup AnalysisPantelis Sarafidis, Rajiv Agarwal, Bertram Pitt, et al.
Diabetes, Obesity & Metabolism|November 13, 2020
Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trialJeroen V Koomen, Jasper Stevens, George Bakris, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 1, 2021
Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE resultsRajiv Agarwal, Stefan D Anker, Gerasimos Filippatos, et al.
Diabetes, Obesity & Metabolism|June 19, 2024
Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trialKathryn Cardoza, Amy Kang, Brendan Smyth, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|October 17, 2022
Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular diseaseGerasimos Filippatos, Stefan D Anker, Bertram Pitt, et al.
Clinical Pharmacology and Therapeutics|March 19, 2014
Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignanciesS Karovic, Y Wen, T G Karrison, et al.
Hypertension (Dallas, Tex. : 1979)|September 28, 2011
Isolated diastolic hypotension and incident heart failure in older adultsJason L Guichard, Ravi V Desai, Mustafa I Ahmed, et al.
Journal of the American Society of Nephrology : JASN|September 25, 2010
Malnutrition-inflammation modifies the relationship of cholesterol with cardiovascular diseaseGabriel Contreras, Bo Hu, Brad C Astor, et al.
Pageof 74

Showing results (641-650 of 738) with videos related to

Sort By:
Pageof 74
Kidney Medicine|December 4, 2023
Finerenone in Black Patients With Type 2 Diabetes and CKD: A Post hoc Analysis of the Pooled FIDELIO-DKD and FIGARO-DKD TrialsJohn M Flack, Rajiv Agarwal, Stefan D Anker, et al.
The American Journal of Medicine|July 3, 2007
Body weight changes with beta-blocker use: results from GEMINIFranz H Messerli, David S H Bell, Vivian Fonseca, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 17, 2023
Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup AnalysisPantelis Sarafidis, Rajiv Agarwal, Bertram Pitt, et al.
Diabetes, Obesity & Metabolism|November 13, 2020
Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trialJeroen V Koomen, Jasper Stevens, George Bakris, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 1, 2021
Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE resultsRajiv Agarwal, Stefan D Anker, Gerasimos Filippatos, et al.
Diabetes, Obesity & Metabolism|June 19, 2024
Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trialKathryn Cardoza, Amy Kang, Brendan Smyth, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|October 17, 2022
Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular diseaseGerasimos Filippatos, Stefan D Anker, Bertram Pitt, et al.
Clinical Pharmacology and Therapeutics|March 19, 2014
Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignanciesS Karovic, Y Wen, T G Karrison, et al.
Hypertension (Dallas, Tex. : 1979)|September 28, 2011
Isolated diastolic hypotension and incident heart failure in older adultsJason L Guichard, Ravi V Desai, Mustafa I Ahmed, et al.
Journal of the American Society of Nephrology : JASN|September 25, 2010
Malnutrition-inflammation modifies the relationship of cholesterol with cardiovascular diseaseGabriel Contreras, Bo Hu, Brad C Astor, et al.
Pageof 74